Entera Bio Ltd. Depreciation & Amortization Growth

Depreciation & Amortization Growth of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Depreciation & Amortization Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Depreciation & Amortization Growth for the quarter ending June 29, 2020 was -22.73% (a 112.23% increase compared to previous quarter)
  • Year-over-year quarterly Depreciation & Amortization Growth decreased by -104.29%
  • Annual Depreciation & Amortization Growth for 2019 was 340.74% (a 1232.06% increase from previous year)
  • Twelve month Depreciation & Amortization Growth ending June 29, 2020 was 45.64% (a -71.07% decrease compared to previous quarter)
  • Twelve month trailing Depreciation & Amortization Growth decreased by -70.07% year-over-year
Trailing Depreciation & Amortization Growth for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
45.64% 157.78% 340.74% 152.5%
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Depreciation & Amortization Growth of Entera Bio Ltd.

Most recent Depreciation & Amortization Growthof ENTX including historical data for past 10 years.

Interactive Chart of Depreciation & Amortization Growth of Entera Bio Ltd.

Entera Bio Ltd. Depreciation & Amortization Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -22.73% -10.71%
2019 211.76% 530.0% 842.86% 180.0% 340.74%
2018 -60.47% 25.58%

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.